HALOZYME THERAPEUTICS, INC. (HALO): what the price assumes

In the published model solve dated 2026-Q2, anchored at $109.79, HALOZYME THERAPEUTICS, INC. (HALO) is priced for +12.6% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-27.

Generated: 2026-09-07 · Exported: 2026-09-09 · Source: https://boothcheck.com/report/HALO

Headline

FieldValue
TickerHALO
CompanyHALOZYME THERAPEUTICS, INC.
Current price$109.79/sh
CompositionRoyalties 62% / Product sales, net 27% / Revenues under collaborative agreements 11%

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

FieldValue
Inversion basiswhole-company
Operating margin (value-band context)7.9%
Operating margin today35.9%
Margin compression (value-band)-28.0pp
Implied growth12.6%
Multiple paid24x operating income

The operating-margin figure is value-band context at year 5: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 7.9% cost of capital with 4% terminal growth over a 5-year stage.

How unusual the bet is: within-range (limited comparison data)

ReferenceValue
vs own history+0.08σ
cohort percentile (of 115 peers)55

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

FamilyMedian price/FVModelsReads
Asset2.20x4expensive
Earnings2.51x4expensive
Relative1.60x3expensive
Growth0.56x3justifies

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 7.9%); the inversion above states its own rate.

Per-Model Detail (n=14)

ModelFamilyFVPrice/FVApplicableMethodology
DCF Perpetual GrowthGrowth$418.550.26xyesFCF base $0.9B, growth 25% (input: historical growth), terminal g 4.0%, WACC 7.9%, 7yr projection
DCF Exit MultipleGrowth$197.060.56xyesExit EV/EBITDA: 20.6x / 23.6x / 26.6x (bear / base = today's held flat / bull), 7yr
Relative ValuationRelative$86.841.26xyesP/E 24x (static sector reference · 2026-04), scenarios: 19.2x / 24.0x / 28.8x (bear / base = reference held flat / bull), EV/EBITDA 16x
Simple DDMGrowth——no—
Two-Stage DDMGrowth——no—
Simple Excess ReturnAsset$39.402.79xyesBV/sh $1.26, ROE (TTM) 288.1%, ke 9.3%
Two-Stage Excess ReturnAsset$2195.800.05xyes5yr excess ROE then converge to ke=9.3%
Discounted Future Market CapGrowth$174.950.63xyesRev $1.7B, growth 30% (input: historical growth; tapered), Terminal P/S: 6.0x / 7.5x / 9.0x (bear / base = today's held flat / bull, cap 12x)
Growth-Adjusted P/ERelative——no—
Margin TrajectoryGrowth——no—
Earnings Power ValueEarnings$24.774.43xyesNormalized EBIT (5y avg op income, one-time charges added back) $0.45B × (1−19%) / WACC 7.9% → EPV (no growth)
Residual IncomeAsset$68.331.61xyesBV $1.26 + 5yr PV of (ROE (TTM) 288.1% − Kₑ 9.3%) × BV; BV grows 8.8%/yr
Graham NumberAsset$9.8711.12xyes√(22.5 × EPS $3.42 × BVPS $1.26) — Graham's conservative floor
EV/EBITDA RelativeRelative$68.791.60xyesEBITDA $0.61B × sector EV/EBITDA 16.0x
FCF YieldEarnings$59.321.85xyesFCF $806.2M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF YieldEarnings$53.312.06xyesSBC-adj FCF $0.74B (FCF $0.81B − SBC $0.06B) capitalized at Kₑ
Ben Graham FormulaEarnings$2.8738.25xyesEPS $3.42 × (8.5 + 2×-5.0%) × (4.4 / 5.3%) (excluded from median)
ROIC-Justified P/BAsset$1.7463.10xyesBV $1.26 × (ROIC 10.9% / WACC 7.9%) (excluded from median)
P/Sales SectorRelative$58.631.87xyesRevenue $1.66B × sector P/S 4.0x
PEG Fair ValueRelative——no—
Earnings YieldEarnings$36.972.97xyesEPS $3.42 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations MultipleRelative——no—
Clinical Phase NPVGrowth——no—
MertonAsset——no—
V5 Mechanical———no—

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

UnitRoleValuation basisRevenueReported profitValue evidenceStatus
Halozyme (consolidated)operatingenterprise1.4B reported-currency—withheldunresolved no unit value

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

FieldValue
Net debt$1.9b
Net debt / NOPAT (after-tax)3.97x
Net debt / operating income (pre-tax)3.21x
Interest coverage29.4x
Share count CAGR (buyback)-3.9%
Burning cashno

Bullet Takeaways

Bull Case

Read Halozyme through the right stage, because mislabeling it is the most common mistake. It looks like a biotech, the sector where cash-flow models break because outcomes are binary, but Halozyme is not waiting on a trial readout to become profitable. It already is profitable, highly so, because it sells a platform rather than a single drug. ENHANZE, its recombinant enzyme technology, lets pharmaceutical partners reformulate blockbuster intravenous drugs into subcutaneous injections that take minutes instead of hours, and Halozyme collects a royalty every time those partners sell the reformulated version. The 10-K confirms the breadth: the company earns "royalties from the sales of ten commercial products including sales of five commercial products from the Roche collaboration, two commercial products from the Janssen collab[oration]." That is a diversified royalty stream across multiple partners and drugs, which is why the operating margin sits near 34%, far above a typical drug developer.

The growth is real and accelerating off a profitable base. First-quarter revenue rose 42% to $376.7 million, with royalty revenue up 43% to $240.7 million, driven by partner products DARZALEX SC, VYVGART Hytrulo, and Phesgo. The 10-K names the same drivers, saying it expects royalties to grow from "anticipated increasing partner product sales of DARZALEX SC, Phesgo and VYVGART Hytrulo, the largest drivers of our royalty revenues." Royalties are the highest-quality revenue a company can have: no manufacturing, no sales force, no clinical risk on the partner's drug, just a cut of someone else's blockbuster. Management guided full-year 2026 royalty revenue to exceed $1 billion for the first time.

The capital allocation confirms management's conviction. Halozyme announced a new $1 billion share repurchase program, and the share count has been falling about 3.4% a year. Net debt is modest against the cash flow, with interest covered more than 26 times over. A company with a high-margin, diversified, growing royalty stream that is also buying back a meaningful chunk of its stock is the opposite of a speculative biotech; it is a cash-generative platform whose stage the market is reading too conservatively at 13 times operating income.

Bear Case

The variable with the most leverage on Halozyme is the one a royalty model cannot escape: the patent clock. Every ENHANZE royalty rests on intellectual property, and that property expires. As the patents underlying each partnered product roll off, the royalty rates step down and eventually end, so a royalty stream that looks like an annuity is actually a depreciating asset with a defined, if extendable, life. The market's modest multiple is the tell: a business growing 42% would normally command a high multiple, and the fact that the price sits below what even a steady decline would warrant means investors are discounting heavily for the eventual royalty fade. The bear case is that the discount is rational, because the durability of the royalty base past the original ENHANZE patent lives is the entire question, and it is genuinely uncertain.

The second pressure is concentration. The 10-K is explicit that DARZALEX SC, Phesgo, and VYVGART Hytrulo are "the largest drivers of our royalty revenues," which means a handful of partner products carry the company. Halozyme does not control those products; its partners do, and a competitive threat to DARZALEX, a pricing action, or a slower-than-expected subcutaneous conversion would flow straight through to Halozyme's royalties with no operational lever to pull. Royalty revenue is also estimated and trued up after the fact, as the 10-K notes payments arrive "approximately 60 days after quarter-end" with a "true-up" if estimates differ, so the company is one step removed from the sales it depends on.

The Merck litigation captures both the opportunity and the risk. Halozyme is suing Merck over the subcutaneous formulation of Keytruda, asserting its MDASE patents, and won a preliminary injunction in Germany. A win could open a large new royalty or settlement stream, but the company itself notes the MDASE patents at issue are not part of the ENHANZE licensing program, so this is a separate, litigated bet rather than contracted revenue, and litigation outcomes are uncertain and slow. Leverage sharpens the downside: net debt at roughly 3.6 times operating income is manageable while royalties grow, but it becomes a heavier weight as the patent fade approaches. The bear case is that a wonderful business with a defined expiry is priced cheaply for exactly that reason, and the cheapness is a warning about durability, not a free lunch.

Valuation

Halozyme presents a genuine puzzle: a business growing revenue 42% with a 34% operating margin that trades at only about 13 times company-wide operating income, a multiple so low the price sits below what even a 5%-a-year decline in operating profit would warrant. The reconciliation is the patent clock. The market is not pricing the current growth; it is pricing the eventual royalty fade, and the low multiple is the discount for an income stream with a defined life.

The families of method split in a way that captures exactly that tension. Asset value and earnings power read the price as expensive, by roughly two times, because they capitalize the trailing royalty earnings and apply a heavy fade. The peer-multiple lens places it modestly above its drug-developer cohort. And the forward-growth method lands well above the price, reading the stock as cheap if the growth persists. That is the whole debate in one pattern: the static, fade-heavy methods say expensive because they assume the royalties decline; the growth method says cheap because the royalties are still rising fast. The buyer's view of the patent durability decides which is right, and the methods cannot settle it.

Solvency is comfortable enough to make this a valuation question rather than a survival one. Net debt of roughly $1.8 billion runs at about 3.6 times operating income, but interest is covered more than 26 times over, and the company generates substantial cash, which it is returning through a new $1 billion buyback and a share count falling about 3.4% a year. The downside is not financial; it is the royalty cliff and the partner concentration. A buyer at this price is underwriting the durability of the ENHANZE royalty base, with optionality from the MDASE patent litigation against Merck on top, paying a low multiple that already assumes the fade, and betting that the royalties extend, the pipeline of new partnered products refills the base, and the litigation breaks favorably before the original patents run out.

Catalysts

Halozyme's first quarter of 2026 was a clear beat. Total revenue rose 42% to $376.7 million, royalty revenue rose 43% to $240.7 million on strength in DARZALEX SC, VYVGART Hytrulo, and Phesgo, and the company reported GAAP earnings per share of $1.22. Alongside the results it announced a new $1 billion share repurchase program and reiterated full-year 2026 guidance, including total revenue of $1.71 to $1.81 billion and royalty revenue of $1.13 to $1.17 billion, the first year royalties are expected to exceed $1 billion.

The Merck patent litigation is the highest-leverage catalyst. Halozyme sued Merck over the subcutaneous formulation of Keytruda, asserting its MDASE delivery patents, and the Munich Regional Court found imminent infringement for Keytruda SC in Germany, requiring Merck to halt in-scope launch activities there. Because the MDASE patents are separate from the ENHANZE licensing program, a favorable outcome would represent new value rather than contracted revenue, so each ruling in the U.S. and European cases is a discrete event that can move the stock.

The variables that move the fundamental story are the sales trajectory of the partner products that drive royalties, the pace at which new ENHANZE collaborations launch to refill the royalty base ahead of patent expirations, and the cadence of the buyback. The next quarterly report will show whether royalty growth tracks toward the billion-dollar guidance and whether new partnered products are reaching the market to extend the platform's life.

Peer Cohorts (Per Segment, With Filing Citations)

Halozyme (consolidated) (reported)

Methodology Note

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.

Sources

Halozyme Q1 2026 results · Halozyme press release, MDASE litigation

View the full interactive HALO report on boothcheck